(AFP / SEBASTIEN BOZON)
The Swiss pharmaceutical giant Roche will buy the American Poseida Therapeutics for 1.5 billion dollars (1.4 billion euros), it announced on Tuesday.
The group will offer its shareholders $9 per share to which will be added $4 per share in the form of a certificate to acquire this biopharmaceutical company based in San Diego, California, which will allow it to strengthen its position in CAR cell therapies. T, he said in a press release.
The price represents a premium of approximately 215% to Poseida’s closing price on November 25.
The agreement to buy the company received unanimous approval from both the Poseida and Roche boards.
Poseida Therapeutics’ portfolio includes cell therapies for hematologic cancers, solid tumors and autoimmune diseases.
CAR-Ts are innovative therapies, which consist of taking cells from the patient’s immune system and then genetically modifying them in order to fight diseases.
The Swiss group, the world number one in oncology, hopes to close the transaction during the first quarter of 2025.
Business
